You are here

Akcea

Early November Brings More Quarterly Reports

Early November Brings More Quarterly Reports

BioSpace

Flag link:

FDA clears rare disease therapy from Akcea, Ionis

FDA clears rare disease therapy from Akcea, Ionis

Biopharma Dive

Ionis Pharmaceuticals

hATTR amyloidosis

Flag link:

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

CP Wire

hereditary ATTR amyloidosis

Flag link:

Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms

Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms

Xconomy

Ionis Pharmaceuticals

transthyretin amyloidosis

Flag link:

Ionis-spinout Akcea prices IPO below expected range

Ionis-spinout Akcea prices IPO below expected range

Drug Delivery Business News

Flag link:

Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch

Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch

Endpoints

Flag link: